Imfinzi puts its flag on the Matterhorn
A hit on EFS will challenge regulators, and points to Merck's design blunder in Keynote-585.
Merck and Sanofi sound the alarm for ILT inhibition
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
Merck takes on the TROP2 leaders again in breast cancer
The company is starting a phase 3 trial of sacituzumab tirumotecan in first-line TNBC.
ASCO-GU – another strike against Cabometyx
A triplet did worse than control in first-line kidney cancer.
Merck gets saci in ovarian
Sacituzumab tirumotecan joins raludotatug deruxtecan on the ovarian cancer pivotal stage.
ASCO-GU – Arcus goes it alone in HIF2α
Casdatifan yields its first median PFS number, but Gilead doesn’t opt in.
What future for Lag3 blockade?
Opdualag chalks up another failure, this time in the extension of an approved use.
ASCO-GU – Pfizer eyes broader Talzenna use
But the overall survival benefit in prostate cancer is still driven by HRR mutations.
